These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8787894)

  • 21. A peptide inhibitor of human immunodeficiency virus infection binds to novel human cell surface polypeptides.
    Henderson LA; Qureshi MN
    J Biol Chem; 1993 Jul; 268(20):15291-7. PubMed ID: 8325899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells.
    Ashorn PA; Berger EA; Moss B
    J Virol; 1990 May; 64(5):2149-56. PubMed ID: 2109100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer.
    Litwin V; Nagashima KA; Ryder AM; Chang CH; Carver JM; Olson WC; Alizon M; Hasel KW; Maddon PJ; Allaway GP
    J Virol; 1996 Sep; 70(9):6437-41. PubMed ID: 8709277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surface expression of the HIV-1 envelope proteins in env gene-transfected CD4-positive human T cell clones: characterization and killing by an antibody-dependent cellular cytotoxic mechanism.
    Ahmad A; Yao XA; Tanner JE; Cohen E; Menezes J
    J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):789-98. PubMed ID: 7912729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins.
    Johnson JE; Schnell MJ; Buonocore L; Rose JK
    J Virol; 1997 Jul; 71(7):5060-8. PubMed ID: 9188571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates.
    Chabot DJ; Zhang PF; Quinnan GV; Broder CC
    J Virol; 1999 Aug; 73(8):6598-609. PubMed ID: 10400757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing.
    Blair WS; Cao J; Jackson L; Jimenez J; Peng Q; Wu H; Isaacson J; Butler SL; Chu A; Graham J; Malfait AM; Tortorella M; Patick AK
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3554-61. PubMed ID: 17646410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly Synergistic when Linked to a CD4-Binding Adnectin.
    Wensel D; Sun Y; Davis J; Li Z; Zhang S; McDonagh T; Fabrizio D; Cockett M; Krystal M
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29743355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of N-linked glycans in the interaction between the envelope glycoprotein of human immunodeficiency virus and its CD4 cellular receptor. Structural enzymatic analysis.
    Fenouillet E; Clerget-Raslain B; Gluckman JC; Guétard D; Montagnier L; Bahraoui E
    J Exp Med; 1989 Mar; 169(3):807-22. PubMed ID: 2538547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The alpha-glucosidase inhibitor 1-deoxynojirimycin blocks human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step.
    Papandréou MJ; Barbouche R; Guieu R; Kieny MP; Fenouillet E
    Mol Pharmacol; 2002 Jan; 61(1):186-93. PubMed ID: 11752220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of an anti-HIV peptide, T22, with gp120 and CD4.
    Tamamura H; Otaka A; Murakami T; Ishihara T; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N
    Biochem Biophys Res Commun; 1996 Feb; 219(2):555-9. PubMed ID: 8605026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity.
    Wensel D; Sun Y; Li Z; Zhang S; Picarillo C; McDonagh T; Fabrizio D; Cockett M; Krystal M; Davis J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains.
    Berson JF; Long D; Doranz BJ; Rucker J; Jirik FR; Doms RW
    J Virol; 1996 Sep; 70(9):6288-95. PubMed ID: 8709256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
    Esser MT; Mori T; Mondor I; Sattentau QJ; Dey B; Berger EA; Boyd MR; Lifson JD
    J Virol; 1999 May; 73(5):4360-71. PubMed ID: 10196334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temperature dependence of cell-cell fusion induced by the envelope glycoprotein of human immunodeficiency virus type 1.
    Frey S; Marsh M; Günther S; Pelchen-Matthews A; Stephens P; Ortlepp S; Stegmann T
    J Virol; 1995 Mar; 69(3):1462-72. PubMed ID: 7853478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events.
    Thali M; Furman C; Helseth E; Repke H; Sodroski J
    J Virol; 1992 Sep; 66(9):5516-24. PubMed ID: 1501286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracellular diversion of glycoprotein GP160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy.
    Lin X; Dashti A; Schinazi RF; Tang J
    FASEB J; 1993 Aug; 7(11):1070-80. PubMed ID: 8370478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
    Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41.
    Labrosse B; Pleskoff O; Sol N; Jones C; Hénin Y; Alizon M
    J Virol; 1997 Nov; 71(11):8230-6. PubMed ID: 9343174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.